Notícias

Don't wait until they recover to initiate positions.

David Denton’s appointment, effective Aug. 17, comes as the company struggles to execute its turnaround.

The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.

Before its fifty percent surge, the drug giant was repeatedly telling a story about its future that the market seemed to be ignoring.

Pfizer Inc. (NYSE:PFE) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 20, 2026, Pfizer Inc. (NYSE:PFE) CEO Albert Bourla said on “In Good Company” that pandemic-era urgency allowed an eight-month COVID vaccine timeline. He said that regulators and governments “reverted to more conservative” approaches afterward. […]

Everyone is still arguing about Novo Nordisk (NYSE:NVO), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector into a multi-year hype cycle. But here’s what you should actually be watching. The reality check has already started, and the numbers are uglier than the headlines ... Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Pfizer (NYSE:PFE) reported that its late stage lung cancer drug sigvotatug vedotin did not significantly improve overall survival in a pivotal Phase 3 trial. The trial compared sigvotatug vedotin to standard chemotherapy docetaxel in patients with metastatic non squamous non small cell lung cancer. The drug, part of the Seagen portfolio acquired for US$43b, showed a manageable safety profile and encouraging signals in a subset of patients, but the main efficacy goal was not met. For Pfizer,...

PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.

Pfizer shares fell about 1.5% after sigvotatug vedotin failed to significantly improve survival in a late-stage lung cancer trial.

The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival compared with chemotherapy medicine docetaxel.

Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) just delivered Q1 2026 results that read like two different chapters of the same drug industry. Lilly is sprinting through an obesity gold rush. Pfizer is rebuilding after COVID and buying its way into the same race. Both beat estimates, but the businesses underneath could not feel ... Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow

Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.

While Wall Street fretted over the future of its biggest blockbuster, a pair of new drugs were already showing the company's next act was well underway.

SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.

Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.

Global Healthcare Opportunities and CBC Group discussed launching a new global fund after their merger, the firms’ heads said, as the healthcare investors move to tap into Asia’s rise as an innovation hub.

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week. Earned income depends on showing up. Dividend income depends on a board of directors ... Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income

Pfizer Inc. (NYSE:PFE) is one of the most undervalued NYSE stocks to invest in. On June 18, Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15 to pursue a new professional opportunity in the consumer goods industry. The company has appointed Cecile Guegan, currently Senior Vice President of Finance for […]

Novo Nordisk (NYSE:NVO)'s majority owner has launched a large pan European research program focused on obesity and cardiometabolic diseases. The initiative aims to speed up research, support startups, and feed potential candidates into Novo Nordisk's future drug pipeline. Pfizer is expanding efforts in obesity treatments, including plans for a first in class monthly GLP 1 therapy and broader clinical trials. Novo Nordisk is a central player in obesity and diabetes care, and this new...

Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b pharmaceutical group is positioned, with value metrics and recent returns drawing closer scrutiny. See our latest analysis for Pfizer. Pfizer’s recent share price has softened, with the stock down 6.53% on a 90 day share price return basis, while the 1 year total shareholder return of 12.52% reflects a different experience for investors over a longer period. If Pfizer’s recent...

Pfizer is out of favor right now, and for good reason, but dividend investors may want to take the risk just the same.

Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.

While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

Pfizer (PFE) reached $25.22 at the closing of the latest trading day, reflecting a -2.72% change compared to its last close.

The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.